Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. ScandiDos AB's accounts receivables for the quarter that ended in Apr. 2026 was kr9.92 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
ScandiDos AB's Days Sales Outstanding for the quarter that ended in Apr. 2026 was 63.97.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. ScandiDos AB's Net-Net Working Capital per share for the quarter that ended in Apr. 2026 was kr-0.06.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
ScandiDos AB's Days Sales Outstanding for the quarter that ended in Apr. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), ScandiDos AB's accounts receivable are only considered to be worth 75% of book value:
ScandiDos AB's Net-Net Working Capital Per Share for the quarter that ended in Apr. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
ScandiDos AB Accounts Receivable Related Terms
ScandiDos AB Accounts Receivable Historical Data
* Premium members only.
The historical data trend for ScandiDos AB's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of kr9.92 Mil mean?
ScandiDos AB (OSTO:SDOS) has a Accounts Receivable of kr9.92 Mil as of Apr. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on ScandiDos AB and its competitors.
Is ScandiDos AB's Accounts Receivable too high?
ScandiDos AB's current Accounts Receivable is kr9.92 Mil. Overall, ScandiDos AB has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ScandiDos AB's Accounts Receivable compare to ABT and SYK?
ScandiDos AB's Accounts Receivable of kr9.92 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Devices & Instruments company?
A good Accounts Receivable depends on the Medical Devices & Instruments industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on ScandiDos AB and its competitors. ScandiDos AB's current Accounts Receivable is kr9.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ScandiDos AB stock overvalued right now?
Based on GuruFocus' analysis, ScandiDos AB (OSTO:SDOS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.13, compared to a current price of kr0.86 — trading 23.9% below its estimated fair value. The current Accounts Receivable is kr9.92 Mil. ScandiDos AB's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For ScandiDos AB (OSTO:SDOS), the current Accounts Receivable is kr9.92 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ScandiDos AB (OSTO:SDOS) Overvalued in 2026?
Based on GuruFocus' analysis, ScandiDos AB stock appears to be undervalued.
The current stock price of kr0.86 is trading 23.9% below its estimated GF Value™ of kr1.13.
GuruFocus considers ScandiDos AB to be Modestly Undervalued.
Key valuation signals for OSTO:SDOS:
Accounts Receivable: kr9.92 Mil
GF Value™: kr1.13 vs. price of kr0.86 (23.9% below fair value)
No single metric tells the full story. See the OSTO:SDOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ScandiDos AB is engaged in providing radiation therapy for cancer. Its product, Delta4 Phantom+, and its various hardware and software options are at the heart of everything ScandiDos does, from product development and production to marketing, sales, and customer support. With Delta4 HexaMotion ScandiDos has successfully developed a motion platform that recreates the movement of the tumor in six dimensions and independently simulates the patient's breathing movement.
48GF Score
Get the complete analysis for OSTO:SDOS
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SDOS has been successfully added to your 
